HOME >> MEDICINE >> NEWS
NIH halts use of COX-2 inhibitor in large cancer prevention trial

The National Institutes of Health (NIH) announced today that it has suspended the use of COX-2 inhibitor celecoxib (Celebrex Pfizer, Inc.) for all participants in a large colorectal cancer prevention clinical trial conducted by the National Cancer Institute (NCI). The study, called the Adenoma Prevention with Celecoxib (APC) trial, was stopped because analysis by an independent Data Safety and Monitoring Board (DSMB) showed a 2.5-fold increased risk of major fatal and non-fatal cardiovascular events for participants taking the drug compared to those on a placebo.

Additional cardiovascular expertise was added to the safety monitoring committees at the request of the Steering Committees for this trial after a September 2004 report that the COX-2 inhibitor rofecoxib (Vioxx) caused a two-fold increased risk of cardiovascular toxicities in a trial to prevent adenomas. The APC is a study of more than 2,000 people who have had a precancerous growth (adenomatous polyp) removed. They were randomized to take either 200 mg of celecoxib twice a day, 400 mg of celecoxib twice a day, or a placebo for three years. The trial began in early 2000 and is scheduled to have been completed by Spring 2005.

Investigators at the 100 sites in the APC trial located primarily in the United States, with a few additional sites in the United Kingdom, Australia, and Canada, have been instructed to immediately suspend study drug use for all participants on the trial, although the participants will remain under observation for the planned remainder of the study.

"Data from the report on rofecoxib (Vioxx) informed us of the need to focus on specific cardiovascular issues, and our Institutes brought in the experts to do so, said Elias A. Zerhouni, M.D., NIH Director. "Our overwhelming commitment is to advance the health and to protect the safety of participants in clinical trials. We are examining the use of these agents in all NIH-sponsored clinical studies. In addition, we
'"/>

Contact: John Burklow / Don Ralbovsky
301-496-5787
NIH/Office of the Director
17-Dec-2004


Page: 1 2

Related medicine news :

1. Success of new treatment halts international blood pressure drug trial
2. Researchers identify brain protein that halts progression of Alzheimers
3. New oral medication halts blindness in AIDS patients
4. Enzyme halts muscle waste in mouse models of most-common childhood muscular dystrophy
5. COX-2 inhibitors associated with blood pressure elevation
6. COX-2 product offers good and bad news in test tube strokes
7. COX-2 inhibitor increases the risk of heart attack in elderly adults with no history of heart attack
8. More studies on risks and benefits of COX-2 inhibitors published in Archives of Internal Medicine
9. Special JAMA commentary on lessons learned from troubles with COX-2 inhibitors
10. Estrogen-associated COX-2 pathways explain protection from heart disease in female mice
11. COX-2 inhibitor could be safest anti-inflammatory drug for older people

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/12/2018)... ... September 13, 2018 , ... Donaldson Plastic Surgery has been included on the ... First's Fast 50 list of central Ohio's fastest growing businesses. The plastic surgery practice ... 81 percent. It is the only medical practice and plastic surgery office to make ...
(Date:9/7/2018)... ... September 07, 2018 , ... The OSHA Training Institute ... OTI Education Center headquartered in Northern California, is shining a spotlight on OSHA’s ... retaliation in response to engaging in activity protected under 22 whistleblower statutes. Protected ...
(Date:9/2/2018)... ... 2018 , ... Eaton Hotel in Washington, DC is a ... opened this week, inspires creativity and innovation among its guests, whether they are ... currently features 209 hotel rooms, a wellness center, a radio station, a meeting ...
(Date:9/1/2018)... ... 01, 2018 , ... September is Animal Pain Awareness Month, ... (IVAPM) that aims to encourage pain management for all animals through education and ... pet owners of the many forms of pain and the importance of pain ...
(Date:8/31/2018)... ... 2018 , ... The social impact documentary feature film on homelessness, OFF THE ... researcher Luciana Lagana, aka Dr. Luciana, has been faring well at film festivals ... Festival, IndieFEST Film Awards, Shawna Shea Memorial Film Festival, and Top Indie Film Awards. ...
Breaking Medicine News(10 mins):
(Date:9/7/2018)... ... September 06, 2018 , ... CTL ... to purchase its commercial spine business, which includes its complete portfolio of spine-related ... spine that result from it. The deal will make CTL Medical the world’s ...
(Date:9/7/2018)... ... , ... New York City is currently the epicenter of the tennis world, ... the fourth and final jewel in the 2018 grand slam crown – The US ... will the players’ footwork be highlighted. , “Today’s tennis isn’t that of your grandmother,” ...
(Date:9/1/2018)... (PRWEB) , ... August 31, 2018 , ... ... Committee have launched the College’s search for a Vice President/ Dean of Academic ... Dean of Academic Affairs (VP/Dean AA) is the chief academic officer responsible for ...
Breaking Medicine Technology:
Cached News: